bluebird bio, Inc.
(NASDAQ : BLUE)

( )
BLUE PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
TSROTESARO, Inc.
-0.27%73.4614.4%$569.48m
AMGNAmgen Inc.
-1.57%187.101.2%$545.46m
GILDGilead Sciences, Inc.
-0.43%64.840.9%$536.21m
CELGCelgene Corporation
-2.20%66.631.2%$484.48m
BIIBBiogen Inc.
-5.86%294.751.3%$368.52m
ILMNIllumina, Inc.
0.87%313.583.5%$340.51m
REGNRegeneron Pharmaceuticals, Inc.
-1.73%369.002.6%$264.69m
VRTXVertex Pharmaceuticals Incorporated
-1.65%163.431.9%$212.48m
AAgilent Technologies, Inc.
0.22%68.001.5%$210.52m
ALXNAlexion Pharmaceuticals, Inc.
-3.23%105.992.0%$152.62m
INCYIncyte Corporation
-0.86%64.262.5%$97.13m
EXASExact Sciences Corporation
1.03%67.8025.3%$97.02m
BLUEBluebird Bio, Inc.
-1.09%103.4314.4%$90.69m
SRPTSarepta Therapeutics, Inc.
-6.64%108.0215.4%$84.06m
NKTRNektar Therapeutics
4.63%35.745.5%$83.18m

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. It offers the LentiGlobin which is a treatment for transfusion-dependent ß-thalassemia; and Lenti-D as a treatment for cerebral adrenoleukodystrophy. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.